Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

- Priority Review Granted with Action Date of August 17 - - Australia and Canada Regulators Will Review Applications as Part of FDA’s Project Orbis - BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 45...

Full "IntellAsia: Resources" article